e- ISSN 0976-0342
Print ISSN 2229-7456

International Journal of Pharmacy & Therapeutics

Journal homepage: www.ijptjournal.com

Review article

A CURRENT BROAD SUMMARY OF RHEUMATOID ARTHRITIS

Mrs. HARI.V[1]*, D. DURGA PRASAD[2], NL. SWATHI[2], P. SHIVA DATTA SAI[2], B. SREEJA[2]

Associate professor, Department of pharmacology, Sri Venkateswara College of Pharmacy, RVS Nagar, Tirupathi Road, Chittoor, Andhra Pradesh, India, 517127.

ABSTRACT

Rheumatoid arthritis is a chronic, inflammatory, autoimmune disease characterized by symmetric inflammation of synovial joints and progressive erosion of cartilage and bone. The American College of Rheumatology guidelines recommend that newly diagnosed patients with rheumatoid arthritis begin treatment with disease-modifying antirheumatic drugs to mitigate joint destruction, preserve function, and prevent disability within 3 months of diagnosis. In recent years, new and emerging therapies have been measured by methotrexate, which remains the most prescribed Disease modifying antirheumatic drugs. A growing understanding of the immunological basis of RA and advances in biotechnology have led to new, targeted biological therapies against proinflammatory cytokines that have effectively changed the treatment paradigm and outcomes of patients with Rheumatoid arthritis. Review of the pharmacological rationale for rheumatoid arthritis therapy is presented in this article, with a focus on currently available biological therapies and those under development. In this article, the pharmacological basis for treating rheumatoid arthritis is reviewed, with an emphasis on biological treatments that are now in use and those that are being developed.

Key Words:- Clinical Signs Of Rheumatoid Arthritis, New Treatment Regimens, And Evaluating Variables.

Access this article online

Home page: http://ijptjournal.com/

Quick Response code

Received:15.06.2022 **Revised**:02.07.2022 **Accepted**:15.08.2022

Corresponding Author

Mrs. Hari. V

Department of pharmacology, Sri Venkateswara College of Pharmacy, RVS Nagar, Tirupathi Road, Chittoor, Andhra Pradesh, India, 517127.

E-mail: vivekrm9@gmail.com.

INTRODUCTION

Rheumatoid arthritis is an autoimmune inflammatory disease that is primarily caused in the synovitis which is also involved in the other organ i.e., interstitial pneumonia and the symptoms of RA includes pain, swelling, stiffness of multiple joints, fever, and malaise. This is highly irreversible condition as of the deformation in joints once started that can't be return back to normal.[1] Its onset is closely related with ecological and hereditary elements. The rate pace of RA is 0.5% to 1% in industrialized countries, and it is considerably higher in ladies and older individuals.[2]

CLINICAL MANIFESTATIONS:

The rheumatoid arthritis patients will be having of the following symptoms:

Joint movement

Hands, wrist, ankles, feet- decreased function

Extra articular findings

Vasculitis felty syndrome or anemia, keratoconjunctivitis sicca

LABORATORY FINDINGS

Erythrocyte sedimentation rate {ESR}, C-reactive protein indicate

Synovial fluid analysis:

Increased WBC count in absence of crystals or infection.

Radiography:

In early stages of RA it shows a swelling of soft tissue and narrowing of joint space

In late stages shows sublaxations, deviations and secondary arthritis [3]

Novel DIAGNOSIS:

1. Serum copper level and HLA – DR typing of a patient with RA useful in predicting RA activity and severity.[4]
2. Increased serum concentration of N- carboxymethyl lysine are related to the presence and severity of RA[5]
3. Biomarkers like C- Reactive protein (CRP), Rheumatoid factor (RF), anti-cyclic citrullinated protein (Anti-CCP), 14-3-3ŋ protein[6]and multi biomarker disease activity (MBDA) This factors are useful in diagnosing and treating RA.
4. Serum amyloid A4 and vitamin D binding proteins are the potential biomarkers related to inflammatory response and joint destruction in RA.[7]

EPIDEMIOLOGY:

1. According to the Meta analysis study total global prevalence of RA estimation is 0.46% with a 95% prediction interval. This study was done with healthy and RA patients. This statistics were given according to global prevalence.[8]
2. According to study questionnaire conducted among 44,551 adults and 3,393 were listed as suspected lists of RA. Through this study a prevalence of 0.75% persons were confirmed with RA. At this rate, by these studies it would be given a total of 7 million patients suspected or having a prevalence of RA. This statistics were given according to Indian population.[9]

Evaluating variables

DAS28 was supplied as a composite calculation in accordance with the American Rheumatism Association Criteria for diagnosing RA (Disease Activity Score)

Four criteria are used to assess DAS.

- The proportion of swollen joints among the 28 specified joints.
- How many of the 28 joints listed above are tender out of the total
- The rate of erythrocyte sedimentation (ESR)
- The patient's perception of their health

The disease score will be determined based on the interpretation provided above.

- DAS28 > 5.1 indicates high disease activity.
- Moderate disease activity -DAS28 > 3.22 to 5.1
- DAS28 > 2.6 to 3.2, little disease activity
- Category of emissions: DAS28 2.6(10)

PATHOGENISIS OF RHEUMATOID ARTHRITIS

It is assessed that 50-80% of RA patients consists of autoantibodies. As depicted over, the presence of autoantibodies has permitted the ID of subgroups of RA patients that are not just more homogenous with respect to take a chance with factors yet additionally in regards to the clinical sickness course. RF, an autoantibody coordinated against the Fc a piece of human IgG, was the primary autoantibody framework to be portrayed in RA. All the more as of late, antibodies against other post translationally changed proteins, i.e., carbamylated and acetylated proteins were distinguished. Seropositive RA is related with expanded radiographic movement and may harm joints, while seronegative RA patients have higher inflammation boundaries at show. Besides, inspiration for a solitary auto immune response as well as rather the conjoined presence of numerous auto antibodies may be important for portraying unmistakable aggregates of RA patients. Auto antibodies not simply give valuable data on sickness result yet in addition offer bits of knowledge into the advancement of RA [11]

The component behind set off RA is believed to be because of the innate immunity. Cigarette smoking prompts peptidyl arginine deiminase (PAD) articulation in alveolar macrophages, which prompts the transformation of arginine to citrulline in the aviation route. This interaction makes a "neoantigen" that enacts a resistant reaction and prompts the development of hostile to citrullinated protein antibodies (ACPAs) [12].

Anti-carbamylated protein (anti-CarP) antibodies are anti posttranslationally changed protein antibodies (AMPA) related with RA. Carbamylation is a cyanide-interceded synthetic response in which lysine is changed over into homocitrulline. The structure of homocitrulline is like citrulline. Anti- CarP antibodies are particular antibodies that have been related with RA in both ACPA-positive and ACPA-negative patients [12].

The furthest down the line expansion to AMPAs in RA patients is anti- acetylated protein antibodies which have been depicted in roughly 40% of RA patients, predominantly in the ACPA-positive group. Detection rates in seronegative RA patients were equivalent to patients with settling arthritis, making it impossible that these antibodies will be a new biomarker supportive for diagnosing RA [11]. Acetylation is an enzymatic reaction remembered to be interceded by microscopic organisms, which might give the connection to RA and microbiome dysbiosis. But the exact mechanism is not yet clears [12].

It is speculated that a second ecological trigger is expected to cause clinically obvious infection. At the point when this is laid out, a damaging inflammation starts. Fibroblast-like synoviocytes (FLS) move from one joint to another, prompting moderate joint damage [12].

Synovial cells keep up with the consistent condition of the joint by discharging hyaluronic corrosive and lubricin for joint grease and capacity, as well as

handling byproducts. In RA, the brokenness of FLS prompts hyperplastic synovium. The strange expansion of FLS results from a deficiency in RA by producing inflammatory cytokines and proteinases i.e., metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) that continues the joint annihilation and make a suitable environment for T cell and B cell and neutrophil accumulation. This is one of the related hypotheses regarding the cause of hyperplastic synovium [13].

TREATMENT:

Current available treatment for rheumatoid arthritis

RA is an auto immune disorder which can't be treated and it can only have a symptomatic and suppressant treatment.

If a patient was diagnosed then DMARD'S are the first option to be chosen. These DMARD's are of two types (a) traditional DMARD's and (b) biological DMARD's. The traditional DMARD's are potent acting drugs by suppressing immune response by blocking protein synthesis and inflammatory cascade as a result it reduces damage to bone, cartilage and it causes a slow progression of disease where as the biological DMARD's are target specific, it has a selective a mechanism of action (interference with a cytokine production, functions and inhibit T-cells, B-cell activation). These biological DMARD's can be altered by pre and probiotics, herbal medicines [14].

Developing medications

The clinically developing drugs for RA are TNF inhibitors (i.e., Adalimumab), interleukin-6 (IL-6) inhibitors (sarilumab, sirukumab, tocilizumab), Janus kinase inhibitors (JAK inhibitors) i.e., tofacitinib, baricitinib, upadacitimib. A combination of methotrexate and upadacitimib are more effective than methotrexate and adalimumab combination for decreasing pain and increasing of efficacy.[15]

Nanomedicine for treating RA: It's a new therapeutic strategy efficiently localize drugs in inflamed joints. These are more efficient when compared to others as of these are of having more bioavailability and bioactivity, therapeutics by enabling selective drug targeted damaged joints.[16] Naringenin nanocrystals found in citrus fruits and tomatoes which are of having higher concentration of anti-oxidants and anti-inflammatory components. These are clinically developing capsule for treating RA. [17]

NEWER MEDICATIONS:

Leflunomide is an oral medication that is converted to malononitrilamide, which inhibits nothe synthesis of ribonucleotide uridine monophosphate pyrimidine. It is suggested to use with the combination of MTX (methotrexate) .which is a chemotherapeutic agent used in immune system suppressant, which inhibited the proliferation of lymphocytes in the patient of RA .This combination therapy is useful in reducing the pain and retards the inflammation [18]

Anakinra is a interleukin-1 receptor antagonist (IL-1Ra) which can be used as monotherapy or combination therapy which have shown the therapeutic effect in RA. The extent of clinical improvement would be seen with expanding dosages of anakinra. It is injected subcutaneously daily [18]

Rituximab is a newer drug that is used in RA which mainly acts by depleting the B- cells that cause the inflammation and abnormal antibodies Rituximab is an effective and relatively safe biological agent in the treatment of RA. It is an option to be considered in patients who are refractory or intolerant to the anti-TNF biologics. [18]

Developing technique used in the RA:

Osseointegration is one of the techniques used in RA a patient which is a bone ingrowth around the metal implants placed in the body. This has improved the quality of life in some patients. In one of the recent studies on the patients of 51 and 65 years old with low dose of methotrexate and other anti-rheumatoid drugs. They have successfully implanted the titanium osseointegration. After the 4 year of follow up they have been satisfied with the results. Stable bone growth was seen around the implants through radiography. [19]

Conclusion

The current therapy is only chosen to alleviate symptoms and ease pain, but there is still a need for therapeutic action that can prevent and cure the disease. As a result, more knowledge about the disease is needed, as well as research into the involvement of various factors that can limit the disease and the development of new drugs.

REFERENCES

Tanaka, Y. Rheumatoid arthritis. Inflamm Regener 40, 20 (2020).

Yin, Xiangjun PhD; Cheng, Fafeng PhD; Wang, Xueqian PhD∗; Mu, Jie PhD; Ma, Chongyang PhD; Zhai, Changming PhD; Wang, Qingguo PhD. Editor(s): Rosenthal., Ken S.

Clinical Pharmacy and Therapeutics by Roger Walker and Cate Whittlesea.

Relationship of serum copper and HLADR4 tissue typing to disease activity and severity in patients with rheumatoid arthritis: A cross sectional Khalid Ahmad Omer Aldabbagh, Dashty Abbas Al-Bustany

Increased serum concentrations of N-carboxymethyllysine are related to the presence and the severity of rheumatoid arthritis. AUTHORS: Ines Knani Hassan Bouzidi Saoussen Zrour Naceur Bergaoui Mohamed Hammami Mohsen Kerkeni

Biomarker Approach towards Rheumatoid Arthritis Treatment. Hitesh Malhotra, Vandana Garg, Govind Singh

IJMS, Vol. 20, Pages 4368: Proteomics Approach for the Discovery of Rheumatoid Arthritis Biomarkers Using Mass Spectrometry Mun, Lee, Park, Kim, Lee, Son, Shin, Lim, Kang

Almutairi K, Nossent J, Preen D, Keen H, Inderjeeth C. The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review. Rheumatol Int. 2021 May;41(5):863-877. Epub 2020 Nov 11. PMID: 33175207.

Malaviya AN, Kapoor SK, Singh RR, Kumar A, Pande I. Prevalence of rheumatoid arthritis in the adult Indian population. Rheumatol Int. 1993;13(4):131-4. . PMID:8310203.

Pharmacotherapy: A Pathophysiologic Approach, 11eJoseph T. DiPiro, Gary C. Yee, L. Michael Posey, Stuart T. Haines, Thomas D. Nolin, Vicki Ellingrod

Derksen VFAM, Huizinga TWJ, van der Woude D. The role of autoantibodies in the pathophysiology of rheumatoid arthritis. Semin Immunopathol. 2017 Jun;39(4):437-446. Epub 2017 Apr 27. PMID: 28451788; PMCID: PMC5486798

Chauhan K, Jandu JS, Goyal A, et al. Rheumatoid Arthritis. [Updated 2022 Jun 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-.

Guo, Q., Wang, Y., Xu, D. et al. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res 6, 15 (2018).

The role of microbiome in rheumatoid arthritis treatment. Rahul Bodkhe, Baskar Balakrishnan, Veena Taneja

Comparison of the efficacy and safety indicators of DMARDs for rheumatoid arthritis: A network meta-analysis. Wang, Zunlian; Huang, Min; Yu, Bin; Huang, Yilan; Zheng

[ASAP] Nanomedicine for the Treatment of Rheumatoid Arthritis. Moonkyoung Jeong, Ji-Ho Park

Naringenin nanocrystals for improving anti-rheumatoid arthritis activity. Guangshuai Zhang, Guangyuan Sun, Haishan Guan, Mo

Bullock J, Rizvi SAA, Saleh AM, Ahmed SS, Do DP, Ansari RA, Ahmed J. Rheumatoid Arthritis: A Brief Overview of the Treatment. Med Princ Pract. 2018; 27(6):501-507. Epub 2018 Sep 2. PMID: 30173215;

Parithimarkalaignan S, Padmanabhan TV. Osseointegration: an update. J Indian Prosthodont Soc. 2013 Mar; 13(1):2-6. Epub 2013 Jan 11. PMID: 24431699; PMCID: PMC3602536.

Cite this article:
Mrs. Hari.V, D. Durga Prasad, NL. Swathi, P. Shiva Datta Sai, B. Sreeja. A Current Broad Summary Of Rheumatoid Arthritis. *International Journal of Pharmacy & Therapeutics*, 13(2), 2022, 67-70.